EGFR+ NSCLC
EGFR+ NSCLC
Advertisement
Laura LitwinEGFR+ NSCLC | July 3, 2025
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Read More
Lung Cancers Today EditorsASCO 2025 | July 2, 2025
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Cecilia BrownEGFR+ NSCLC | June 24, 2025
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Raffaele Califano, MDEGFR+ NSCLC | June 24, 2025
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
Laura LitwinEGFR+ NSCLC | June 24, 2025
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
Helena Yu, MDASCO 2025 | June 6, 2025
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Laura LitwinConference Coverage | June 2, 2025
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer W. Carlisle, MDASCO 2025 | June 19, 2025
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Alexander Spira, MD, PhDELCC 2025 | May 8, 2025
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Stephen V. Liu, MDEGFR+ NSCLC | April 24, 2025
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhDELCC 2025 | April 16, 2025
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Cecilia BrownELCC 2025 | March 28, 2025
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Nicolas Girard, MD, PhDELCC 2025 | March 27, 2025
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Cecilia BrownELCC 2025 | March 27, 2025
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Cecilia BrownELCC 2025 | March 27, 2025
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
Cecilia BrownELCC 2025 | March 27, 2025
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Nicolas Girard, MD, PhDELCC 2025 | March 26, 2025
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
Stephen V. Liu, MDEGFR+ NSCLC | February 4, 2025
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
Cecilia BrownEGFR+ NSCLC | February 3, 2025
The CHMP positive opinion is supported by results from the phase 3 PALOMA-3 study.
Cecilia BrownEGFR+ NSCLC | January 30, 2025
Pending discussions with the FDA, officials say there are plans to submit for regulatory approval in the second half of 2025.
Advertisement
Advertisement
Latest News

July 3, 2025